IRIS
LAMBERTINI, MATTEO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 21.230
AS - Asia 91
SA - Sud America 36
NA - Nord America 14
AF - Africa 1
Totale 21.372
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 21.228
CN - Cina 54
BR - Brasile 30
SG - Singapore 19
US - Stati Uniti d'America 14
VN - Vietnam 10
AR - Argentina 3
HK - Hong Kong 2
ID - Indonesia 2
PY - Paraguay 2
FI - Finlandia 1
IQ - Iraq 1
MY - Malesia 1
PK - Pakistan 1
TW - Taiwan 1
UA - Ucraina 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 21.372
Salva come PNG Salva come JPEG
Città #
Genova 9.523
Genoa 8.250
Vado Ligure 1.817
Rapallo 1.564
Bordighera 74
Beijing 25
Singapore 15
Ashburn 14
Curitiba 3
São Paulo 3
Hanoi 2
Hong Kong 2
Adamantina 1
Alfenas 1
Araraquara 1
Arinos 1
Baghdad 1
Barrinha 1
Brasília 1
Brumadinho 1
Buenos Aires 1
Buritis 1
Bắc Giang 1
Camaragibe 1
Campo Mourão 1
Campos dos Goytacazes 1
Canela 1
Ciudad del Este 1
Conselheiro Lafaiete 1
Da Nang 1
Dezhou 1
Ezeiza 1
Fighiera 1
Franco da Rocha 1
Gravataí 1
Guaratuba 1
Ha Long 1
Ho Chi Minh City 1
Hưng Yên 1
Hải Dương 1
Jakarta 1
Johannesburg 1
Karachi 1
Kuala Selangor 1
Lappeenranta 1
Luis Eduardo Magalhães 1
Lấp Vò 1
Mérida 1
Nova Iguaçu 1
Rio Bonito 1
San Alberto 1
São Francisco do Sul 1
São João del Rei 1
Tianjin 1
Vargem Grande Paulista 1
Visconde do Rio Branco 1
Várzea Paulista 1
Zibo 1
Totale 21.338
Salva come PNG Salva come JPEG
Nome #
Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis 213
Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast malignancies: a systematic review and meta-analysis 193
Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak 173
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies 168
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 166
Cancer and fertility preservation: international recommendations from an expert meeting 166
Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies 165
Temporary Ovarian Suppression With Gonadotropin-Releasing Hormone Agonist During Chemotherapy for Fertility Preservation: Toward the End of the Debate? 164
Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence 160
Management of young women with early breast cancer 156
Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO) 155
Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study 152
The five "Ws" for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs) 144
Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: A systematic review and meta-analysis of individual patient–level data 143
Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: Results of an observational study 143
Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis 141
Biology, staging, and treatment of breast cancer during pregnancy: reassessing the evidences 141
Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer 141
The PREgnancy and FERtility (PREFER) study: An Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients 139
News on the medical treatment of young women with early-stage HER2-negative breast cancer 139
Adherence to guidelines in requesting oncotype DX in a publicly funded health care system 139
Pharmacotherapy to protect ovarian function and fertility during cancer treatment 138
New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients 137
State of the art on oocyte cryopreservation in female cancer patients: A critical review of the literature 137
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials 137
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis 136
Treatment with aromatase inhibitors and markers of cardiovascular disease 132
Exploring the safety of chemotherapy for treating breast cancer during pregnancy 132
New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an "ESMO Open-Cancer Horizons" Series 132
Beyond fertility preservation: role of the oncofertility unit in the reproductive and gynecological follow-up of young cancer patients 132
Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial 131
Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients 131
The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients 129
Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer 127
Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients 127
Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials 127
Fertility, sexuality and cancer in young adult women 127
Letrozole withdrawal response in locally advanced breast cancer 124
Another step towards improving oncofertility counselling of young women with Hodgkin's lymphoma 124
Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors? 123
The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients 123
Reply to the letter to the editor 'Can ovarian suppression with gonadotropin releasing hormone analogs (GnRHa) preserve fertility in cancer patients?' by Rodriguez-Wallberg et al. 123
Reply to the letter "Safety of fertility preservation in women with breast cancer" 123
Treatment-induced early menopause and the protective role of gonadotropin-releasing hormone agonists during chemotherapy 122
Gonadotropin Releasing Hormone Agonists Have an Anti-apoptotic Effect on Cumulus Cells 122
Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer 122
Adjuvant trastuzumab: a 10-year overview of its benefit 121
Fertility and pregnancy issues in BRCA-mutated breast cancer patients 121
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients 121
Patterns of care and clinical outcomes of first-line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients relapsing after (Neo)adjuvant trastuzumab: An Italian multicenter retrospective cohort study 121
Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review 121
Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects 119
Diagnosis of lung cancer following emergency admission: Examining care pathways, clinical outcomes, and advanced NSCLC treatment in an Italian cancer Center 118
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study 118
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study 118
Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting 117
Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer 117
Burning Questions in the Oncofertility Counseling of Young Breast Cancer Patients 117
Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis 116
Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives 116
Targeted agents for cancer treatment during pregnancy 114
Safety and feasibility of fasting‐mimicking diet and effects on nutritional status and circulating metabolic and inflammatory factors in cancer patients undergoing active treatment 113
Reply to the letter “Body mass index and clinical outcomes in trastuzumab-treated metastatic breast cancer patients: An alternative explanation for the lack of association” 109
What medical oncologist residents think about the Italian speciality schools: A survey of the Italian Association of Medical Oncology (AIOM) on educational, clinical and research activities 108
Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations 108
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial 108
Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors 106
Controversies in Oncology: Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do? 106
Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology 105
Oncofertility counselling in premenopausal women with HER2-positive breast cancer 105
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: exploratory analysis of the GIM2 trial 104
Assessing the Impact of the COVID-19 Outbreak on the Attitudes and Practice of Italian Oncologists Toward Breast Cancer Care and Related Research Activities 103
Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy 103
Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancer 103
Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer 102
Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer? 102
Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in young BRCA-mutated breast cancer patients 101
Triple-negative breast cancer: Current perspective on the evolving therapeutic landscape 101
Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review 101
Breast cancer treatment-induced cardiotoxicity 100
Implementing the hub and spoke model for the oncofertility units 100
A pooled analysis of the cardiac events in the trastuzumab adjuvant trials 100
Tumor-to-nipple Distance Should Not Preclude Nipple-sparing Mastectomy in Breast Cancer Patients. Personal Experience and Literature Review 100
Breast Cancer Surgery in the COVID-19 Pandemic: Validation of a Preventive Program for Patients and Health Care Workers 100
Adverse events and impact on quality of life of antibody-drug conjugates in the treatment of metastatic breast cancer: A systematic review and meta-analysis 99
Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival A Randomized Clinical Trial 99
Pregnancies in young women with diagnosis and treatment of HER2-positive breast cancer 99
Stevens-johnson syndrome after treatment with bendamustine 97
Debated role of ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in women with cancer 97
Long-term safety of pregnancy following breast cancer according to estrogen receptor status 97
Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer 97
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: A NeoALTTO sub-study (BIG 1-06) 97
Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials 97
Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis 96
Follow-up strategies for women treated for early breast cancer 96
Comparing the gonadotoxicity of multiple breast cancer regimens: Important understanding for managing breast cancer in pre-menopausal women 96
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial 95
Impact of Taxanes, Endocrine Therapy, and Deleterious Germline BRCA Mutations on Anti-müllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based Chemotherapy 94
Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate 94
Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients 93
Totale 12.225
Salva come PNG Salva come JPEG
Categoria #
all - tutte 94.313
article - articoli 94.155
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 158
Totale 188.626
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.673 0 0 0 293 148 132 203 194 139 247 140 177
2021/20222.453 166 82 108 237 58 230 82 523 278 259 98 332
2022/20232.027 265 194 38 162 269 260 53 186 376 16 186 22
2023/20241.623 53 153 38 198 111 143 93 112 87 113 135 387
2024/20254.968 141 376 97 278 671 541 525 768 242 250 490 589
2025/20263.670 1.011 471 1.365 823 0 0 0 0 0 0 0 0
Totale 22.411